
April 10 (Reuters) - Pasithea Therapeutics Corp KTTA.O:
PASITHEA THERAPEUTICS ANNOUNCES POSITIVE SAFETY REVIEW COMMITTEE (SRC) RECOMMENDATION FROM ITS ONGOING PHASE 1 CLINICAL TRIAL OF PAS-004 IN ADVANCED CANCER
PASITHEA THERAPEUTICS CORP - NO DOSE-LIMITING TOXICITIES (DLT'S) OR RASH OBSERVED TO DATE
PASITHEA THERAPEUTICS CORP - SRC RECOMMENDED THAT TRIAL ESCALATE TO NEXT DOSE LEVEL OF 30MG CAPSULE